BCG January 2, 2026
Key Takeaways
Most biopharma companies are running AI pilots, and some are starting to scale those efforts.
- Few, however, have embraced an AI-first mindset, treating AI as the organization’s central nervous system.
- For those that take that bold step, the rewards can be profound: a 5% to 15% revenue uplift and a decisive edge in a competitive industry.
This article and the accompanying slide deck are part of a series exploring how companies in specific industries can adopt the mindset, expertise, and ambition required to win in an AI-first world.
As AI reshapes the biopharmaceutical industry, the unimaginable is becoming tangible: faster discovery, smarter trials, more reliable manufacturing, and new ways of engaging with health care...
Today's Sponsors
Today's Sponsor